Peer-Reviewed Study Validates Accuracy of SANSA Home Sleep Apnea Test

ATLANTA, Ga., June 17, 2025 /PRNewswire/ — Huxley Medical, a commercial-stage medical technology firm focused on streamlining detection of sleep and heart disorders, announced that the clinical validation study of its SANSA home sleep apnea test has been published in Frontiers in Neurology (Volume 16, 2025; doi: 10.3389/fneur.2025.1592690). The multicenter, prospective trial confirms that SANSA delivers comparable performance to in–lab polysomnography (PSG), the recognized gold standard for obstructive sleep apnea (OSA) diagnosis.

The study, titled “Polysomnography validation of SANSA to detect obstructive sleep apnea,” included 340 participants across seven U.S. clinical sites. SANSA’s close agreement with PSG combined with its simple, single-point-of-contact, hands-free design positions it as an efficient and versatile solution to diagnose and monitor OSA.

Study highlights include:

• Scale and diversity: Investigators highlighted the generalizability of the study results due to its large, diverse group of participants across seven academic and community sleep centers using different PSG protocols, exceeding that of most other home sleep testing study validations.
• Diagnostic accuracy: High apnea-hypopnea index (AHI) correlation with consensus PSG (91%), along with sensitivity of 88% and specificity of 87% for detecting moderate-to-severe OSA (AHI ≥ 15 events/hour)
• Total sleep time assessment: Correlation of R = 0.82 between SANSA and PSG-derived measures, with sleep epoch classification accuracy of 87%

“This publication represents an important milestone in the clinical validation of SANSA,” said Dr. Cathy Goldstein, MD, principal investigator on the study, professor of Neurology at the University of Michigan Sleep Disorders Center, and former chair of the American Academy of Sleep Medicine’s Artificial Intelligence in Sleep Medicine Committee. “As providers seek more efficient and scalable ways to diagnose sleep apnea, these findings reinforce that SANSA can deliver reliable, high-quality data without the complexity of traditional home sleep apnea testing devices.”

The SANSA platform uses a wireless chest-worn patch to collect multi-parameter physiological data without the need for phone apps or technician setup. By simplifying testing, SANSA aims to expand access to timely diagnosis and treatment for millions of Americans with undiagnosed sleep apnea. The embedded reference electrocardiogram (ECG) within SANSA’s suite of sensors also enables concurrent measurement of cardiac signals—opening new avenues for broader clinical applications.

About Huxley Medical
Huxley Medical, Inc. is a privately held medical technology company on a mission to develop diagnostic solutions that streamline care for any patient anywhere. The company has received funding from the National Science Foundation, National Institutes of Health, Georgia Research Alliance Venture Fund, Invest Georgia, Georgia Tech Foundation Research Impact Fund, and Duke Capital Partners to translate its growing technology portfolio. To learn more, visit huxleymed.com or email info@huxleymed.com. 

Research manuscript: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1592690/full

Media Contact
Brennan Torstrick
Chief Scientific Officer
Huxley Medical
Brennan.torstrick@huxleymed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/peer-reviewed-study-validates-accuracy-of-sansa-home-sleep-apnea-test-302484213.html

SOURCE Huxley Medical, Inc.